SlideShare a Scribd company logo
1 of 1
www.postersession.com
Contact Information
1505 S. Atlantic Blvd. #E
Alhambra, CA 91803
Email: francislin96@yahoo.com
Tel: (+011-626-281-2637)
SUMMARY OF KEY FINDINGS
The actin binding proteins, Bnr and Bud6, are necessary for normal regulation of actin. Deletion of Bnr and Bud6 results in misregulation of the mutant actins, N115T and R116Q, as well as
increased proliferation of cells expressing these mutations. These findings are depicted in the cell growth curves, doubling times, and growth under stress conditions.
BACKGROUND
• Thoracic Aortic Aneurysm and Dissection (TAAD) is
characterized by dilation and rupture of the aortic wall
• Responsible for 0.5% to 1% of deaths in the U.S. per year
• 20% of the patients inherit the disease
• ACTA2, a gene that codes for α-smooth muscle actin, is the
most common genetic cause of TAAD
• N115T and R116Q are of special interest because their
location on the actin monomer suggests involvement in
intermonomer interactions within the filament
• Formins are actin-binding proteins and are involved in actin
polymerization
OBJECTIVES
• Observe and analyze the regulation of N115T and R116Q
mutations upon deletion of Bnr and Bud6
• Observe mutations under stress conditions
• Hypothesis: Select mutations in actin differentially affect
regulation by a select group of actin-binding proteins that
facilitate polymerization.
VARIABLES
Controls: Wild Type (WT), N115T, and R116Q at 30°C
Manipulated Variables: Mutations – N115T and R116Q
ΔBnr vs. ΔBnrΔBud6
Stress Conditions – 24°C, 30°C, 37°C, YPG, 0.5M NaCl, 0.9M NaCl
Dependent Variables: Doubling Time
Growth Curve
Stress Condition Plates
RESULTS
DISCUSSION
• Cells expressing the mutant actins doubled in growth
approximately 30 minutes faster than WT cells
• ΔBnr strains had a slightly faster doubling time than
ΔBnrΔBud6
• Proposed hypothesis was proven to be correct.
• Deleting Bnr and Bud6 results in misregulation and
excessive proliferation of cells
• Select mutations in actin differentially affect
regulation by a select group of actin-binding proteins
that facilitate polymerization
STUDY IMPLICATIONS
• While both N115T and R116Q mutations cause
TAAD, N115T results in stroke and R116Q results in
coronary artery disease
• The effect of Bnr and Bud6 deletion on cells
expressing N115T and R116Q have not previously
been studied
• Results could provide further insight into the N115T
and R116Q clinical phenotypes
• Complete characterization of ACTA2 mutations could
lead to a better understanding of the clinical
phenotypes and potentially result in improved
treatments
FUTURE RESEARCH
• Repeat experiments to determine accuracy
• Assess effects of ΔBnr and ΔBnrΔBud6 on WT cell
growth and other TAAD mutations
• Further investigation into why N115T and R116Q
have faster doubling times than wild type
• Determine the mutation-specific cause for TAAD
development in ACTA2 mutations
ACKNOWLEDGEMENTS
Heather L. Bartlett
Peter A. Rubenstein
Alyson R. Pierick
Nicole D. Vanderpool
Elesa W. Wedemeyer
Alex Greiner
University of Iowa Biochemistry Department
Regulation of Mutant Actin by Actin-Binding Proteins
Francis Lin
Mentor: Heather Bartlett
Department of Biochemistry, University of Iowa Carver College of Medicine, 51 Newton Rd., Iowa City, Iowa, 52242-1109
Doubling Time
Cell Type Hours
WT 2.63
115* 2.68
N115T ΔBnr 2.15
N115T ΔBnrΔBud6 2.22
116* 2.65
R116Q ΔBnr 2.10
R116Q ΔBnrΔBud6 2.11
0
5
10
15
20
25
30
0 20 40 60 80
O.D.600
Hours
Cell Growth Curve
WT
115*
115 ΔBnr
115 ΔBnr ΔBud6
116*
116 ΔBnr
116 ΔBnr ΔBud6
24°C 37°C
0.5M NaCl 0.9M NaClYPG
*Extrapolated from previous data*Extrapolated from previous data
Legend
1- WT
2- N115T ΔBnr
3- N115T ΔBnrΔBud6
4- R115Q ΔBnr
5- R115Q ΔBnrΔBud6
30°C
1000x
1x
10x
100x
1000x
1x
10x
100x
1000x
1x
10x
100x
1000x
1x
10x
100x
1 2 3 4 53 4 51 2 3 4 51 2 3
4 51 2 3 4 51 2 3 4 51 2 3
1
2
3
4
C
N
N115T
R116Q
Figure 1. Actin Monomer
Figure 2. Actin Filament
Bni1p or
Bnr1p
Actin Filament
Actin Monomer
Pointed End
Barbed EndBni1p and Bnr1p are
yeast formins. They
facilitate the addition of
monomers to the barbed
end of the filament
during polymerization.
Bud6p enhances Bni1p.
SUMMARY OF KEY FINDINGS
• Saccharomyces cerevisiae, or budding
yeast, was used as a model since it is
easy to manipulate. Yeast actin shares
a 94% similarity with human actin.
• A spectrometer was used to determine
total cell density in order to obtain a
growth curve for cells expressing the
mutant actins.
• Spotting of cells was done using 1x,
10x, 100x, and 1000x dilutions. Stress
conditions included 24°C, 30°C, and
37°C. A restricted carbon source
(YPG), 0.5M NaCl, and 0.9M NaCl
were additional stress conditions.
METHODS
The results from the spotting indicates that there is misregulation
among the mutations when Bnr and/or Bud6 are deleted. The
mutations display increased cell density, suggesting that the cell
has lost control of its cell proliferation mechanism.
All other possible
ACTA2 mutations
BACKGROUND
OBJECTIVES
METHODS
VARIABLES
RESULTS
DISCUSSION
STUDY IMPLICATIONS
FUTURE RESEARCH
ACKNOWLEDGEMENTS

More Related Content

What's hot

Hodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment UpdateHodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment Updatespa718
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Updatespa718
 
10.29.07 Coumadin P Gx Jonas
10.29.07 Coumadin P Gx Jonas10.29.07 Coumadin P Gx Jonas
10.29.07 Coumadin P Gx JonasFlavio Guzmán
 
MOLECULAR MONITORING
MOLECULAR MONITORINGMOLECULAR MONITORING
MOLECULAR MONITORINGspa718
 
IMATINIB RESISTANT CML
IMATINIB RESISTANT CMLIMATINIB RESISTANT CML
IMATINIB RESISTANT CMLspa718
 
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide,...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide,...A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide,...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide,...spa718
 
Induction agents in renal transplantation
Induction agents in renal transplantationInduction agents in renal transplantation
Induction agents in renal transplantationVishal Golay
 

What's hot (12)

Hodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment UpdateHodgkin's Lymphoma: Treatment Update
Hodgkin's Lymphoma: Treatment Update
 
Crizo
CrizoCrizo
Crizo
 
Acute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment UpdateAcute Lymphoblastic Lymphoma: Treatment Update
Acute Lymphoblastic Lymphoma: Treatment Update
 
10.29.07 Coumadin P Gx Jonas
10.29.07 Coumadin P Gx Jonas10.29.07 Coumadin P Gx Jonas
10.29.07 Coumadin P Gx Jonas
 
MOLECULAR MONITORING
MOLECULAR MONITORINGMOLECULAR MONITORING
MOLECULAR MONITORING
 
Anticoagulacion oral
Anticoagulacion oralAnticoagulacion oral
Anticoagulacion oral
 
Lrrk2 nww-wood
Lrrk2 nww-woodLrrk2 nww-wood
Lrrk2 nww-wood
 
IMATINIB RESISTANT CML
IMATINIB RESISTANT CMLIMATINIB RESISTANT CML
IMATINIB RESISTANT CML
 
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide,...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide,...A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide,...
A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide,...
 
Induction agents in renal transplantation
Induction agents in renal transplantationInduction agents in renal transplantation
Induction agents in renal transplantation
 
Dabigatran2
Dabigatran2Dabigatran2
Dabigatran2
 
Molecular Diagnostics
Molecular DiagnosticsMolecular Diagnostics
Molecular Diagnostics
 

Similar to Poster

ACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAflasco_org
 
Hyperkalemia, an update
Hyperkalemia, an updateHyperkalemia, an update
Hyperkalemia, an updateJoel Topf
 
Vascular AT1 Receptors in Hypertension Emory Grand Rounds Slideshare Version....
Vascular AT1 Receptors in Hypertension Emory Grand Rounds Slideshare Version....Vascular AT1 Receptors in Hypertension Emory Grand Rounds Slideshare Version....
Vascular AT1 Receptors in Hypertension Emory Grand Rounds Slideshare Version....InsideScientific
 
Stroke & thrombectomy - Dr. Jo Caekebeke
Stroke & thrombectomy - Dr. Jo CaekebekeStroke & thrombectomy - Dr. Jo Caekebeke
Stroke & thrombectomy - Dr. Jo CaekebekeEric Tack
 
Management of SHPT in dialysis and beyond.pptx
Management of SHPT in dialysis and beyond.pptxManagement of SHPT in dialysis and beyond.pptx
Management of SHPT in dialysis and beyond.pptxChristos Argyropoulos
 
Induction treatment in Kidney transplantation chaken 2017
Induction treatment in Kidney transplantation chaken 2017 Induction treatment in Kidney transplantation chaken 2017
Induction treatment in Kidney transplantation chaken 2017 CHAKEN MANIYAN
 
Stroke update 2011
Stroke update 2011Stroke update 2011
Stroke update 2011taem
 
Nuc. med urology .pptx
Nuc. med urology .pptxNuc. med urology .pptx
Nuc. med urology .pptxAnupamAnand59
 
Presentatie maastricht
Presentatie maastrichtPresentatie maastricht
Presentatie maastrichtriannefijten
 
Novel Cardiac biomarkers in Ischemic heart disease
Novel Cardiac biomarkers in Ischemic heart diseaseNovel Cardiac biomarkers in Ischemic heart disease
Novel Cardiac biomarkers in Ischemic heart diseaseChetan Ganteppanavar
 
Vascular Aging – New Lessons From a Novel "Knock-In" Mouse Model
Vascular Aging – New Lessons From a Novel "Knock-In" Mouse ModelVascular Aging – New Lessons From a Novel "Knock-In" Mouse Model
Vascular Aging – New Lessons From a Novel "Knock-In" Mouse ModelScintica Instrumentation
 
Hussein drug therapy in aki 3 osama alshahat 2 pptx
Hussein drug therapy in aki 3 osama alshahat 2 pptxHussein drug therapy in aki 3 osama alshahat 2 pptx
Hussein drug therapy in aki 3 osama alshahat 2 pptxFarragBahbah
 
Topic scleroderma and kidney Chaken Maniyan
Topic scleroderma and kidney Chaken ManiyanTopic scleroderma and kidney Chaken Maniyan
Topic scleroderma and kidney Chaken ManiyanCHAKEN MANIYAN
 
Lo mejor del ACC 2014. Insuficiencia cardiaca, HTA y pericardio
Lo mejor del ACC 2014. Insuficiencia cardiaca, HTA y pericardioLo mejor del ACC 2014. Insuficiencia cardiaca, HTA y pericardio
Lo mejor del ACC 2014. Insuficiencia cardiaca, HTA y pericardioSociedad Española de Cardiología
 

Similar to Poster (20)

ACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIAACUTE MYELOID LEUKEMIA
ACUTE MYELOID LEUKEMIA
 
Cracks in ckd Model
Cracks in ckd ModelCracks in ckd Model
Cracks in ckd Model
 
Hyperkalemia, an update
Hyperkalemia, an updateHyperkalemia, an update
Hyperkalemia, an update
 
Acc 2011, aula
Acc 2011, aulaAcc 2011, aula
Acc 2011, aula
 
Vascular AT1 Receptors in Hypertension Emory Grand Rounds Slideshare Version....
Vascular AT1 Receptors in Hypertension Emory Grand Rounds Slideshare Version....Vascular AT1 Receptors in Hypertension Emory Grand Rounds Slideshare Version....
Vascular AT1 Receptors in Hypertension Emory Grand Rounds Slideshare Version....
 
Stroke & thrombectomy - Dr. Jo Caekebeke
Stroke & thrombectomy - Dr. Jo CaekebekeStroke & thrombectomy - Dr. Jo Caekebeke
Stroke & thrombectomy - Dr. Jo Caekebeke
 
Dilemma in glioma
Dilemma in gliomaDilemma in glioma
Dilemma in glioma
 
Brain
BrainBrain
Brain
 
Management of SHPT in dialysis and beyond.pptx
Management of SHPT in dialysis and beyond.pptxManagement of SHPT in dialysis and beyond.pptx
Management of SHPT in dialysis and beyond.pptx
 
San jose 2011
San jose 2011San jose 2011
San jose 2011
 
Induction treatment in Kidney transplantation chaken 2017
Induction treatment in Kidney transplantation chaken 2017 Induction treatment in Kidney transplantation chaken 2017
Induction treatment in Kidney transplantation chaken 2017
 
Stroke update 2011
Stroke update 2011Stroke update 2011
Stroke update 2011
 
Nuc. med urology .pptx
Nuc. med urology .pptxNuc. med urology .pptx
Nuc. med urology .pptx
 
Presentatie maastricht
Presentatie maastrichtPresentatie maastricht
Presentatie maastricht
 
Novel Cardiac biomarkers in Ischemic heart disease
Novel Cardiac biomarkers in Ischemic heart diseaseNovel Cardiac biomarkers in Ischemic heart disease
Novel Cardiac biomarkers in Ischemic heart disease
 
Vascular Aging – New Lessons From a Novel "Knock-In" Mouse Model
Vascular Aging – New Lessons From a Novel "Knock-In" Mouse ModelVascular Aging – New Lessons From a Novel "Knock-In" Mouse Model
Vascular Aging – New Lessons From a Novel "Knock-In" Mouse Model
 
ACC UPDATE 2018
ACC UPDATE 2018ACC UPDATE 2018
ACC UPDATE 2018
 
Hussein drug therapy in aki 3 osama alshahat 2 pptx
Hussein drug therapy in aki 3 osama alshahat 2 pptxHussein drug therapy in aki 3 osama alshahat 2 pptx
Hussein drug therapy in aki 3 osama alshahat 2 pptx
 
Topic scleroderma and kidney Chaken Maniyan
Topic scleroderma and kidney Chaken ManiyanTopic scleroderma and kidney Chaken Maniyan
Topic scleroderma and kidney Chaken Maniyan
 
Lo mejor del ACC 2014. Insuficiencia cardiaca, HTA y pericardio
Lo mejor del ACC 2014. Insuficiencia cardiaca, HTA y pericardioLo mejor del ACC 2014. Insuficiencia cardiaca, HTA y pericardio
Lo mejor del ACC 2014. Insuficiencia cardiaca, HTA y pericardio
 

Poster

  • 1. www.postersession.com Contact Information 1505 S. Atlantic Blvd. #E Alhambra, CA 91803 Email: francislin96@yahoo.com Tel: (+011-626-281-2637) SUMMARY OF KEY FINDINGS The actin binding proteins, Bnr and Bud6, are necessary for normal regulation of actin. Deletion of Bnr and Bud6 results in misregulation of the mutant actins, N115T and R116Q, as well as increased proliferation of cells expressing these mutations. These findings are depicted in the cell growth curves, doubling times, and growth under stress conditions. BACKGROUND • Thoracic Aortic Aneurysm and Dissection (TAAD) is characterized by dilation and rupture of the aortic wall • Responsible for 0.5% to 1% of deaths in the U.S. per year • 20% of the patients inherit the disease • ACTA2, a gene that codes for α-smooth muscle actin, is the most common genetic cause of TAAD • N115T and R116Q are of special interest because their location on the actin monomer suggests involvement in intermonomer interactions within the filament • Formins are actin-binding proteins and are involved in actin polymerization OBJECTIVES • Observe and analyze the regulation of N115T and R116Q mutations upon deletion of Bnr and Bud6 • Observe mutations under stress conditions • Hypothesis: Select mutations in actin differentially affect regulation by a select group of actin-binding proteins that facilitate polymerization. VARIABLES Controls: Wild Type (WT), N115T, and R116Q at 30°C Manipulated Variables: Mutations – N115T and R116Q ΔBnr vs. ΔBnrΔBud6 Stress Conditions – 24°C, 30°C, 37°C, YPG, 0.5M NaCl, 0.9M NaCl Dependent Variables: Doubling Time Growth Curve Stress Condition Plates RESULTS DISCUSSION • Cells expressing the mutant actins doubled in growth approximately 30 minutes faster than WT cells • ΔBnr strains had a slightly faster doubling time than ΔBnrΔBud6 • Proposed hypothesis was proven to be correct. • Deleting Bnr and Bud6 results in misregulation and excessive proliferation of cells • Select mutations in actin differentially affect regulation by a select group of actin-binding proteins that facilitate polymerization STUDY IMPLICATIONS • While both N115T and R116Q mutations cause TAAD, N115T results in stroke and R116Q results in coronary artery disease • The effect of Bnr and Bud6 deletion on cells expressing N115T and R116Q have not previously been studied • Results could provide further insight into the N115T and R116Q clinical phenotypes • Complete characterization of ACTA2 mutations could lead to a better understanding of the clinical phenotypes and potentially result in improved treatments FUTURE RESEARCH • Repeat experiments to determine accuracy • Assess effects of ΔBnr and ΔBnrΔBud6 on WT cell growth and other TAAD mutations • Further investigation into why N115T and R116Q have faster doubling times than wild type • Determine the mutation-specific cause for TAAD development in ACTA2 mutations ACKNOWLEDGEMENTS Heather L. Bartlett Peter A. Rubenstein Alyson R. Pierick Nicole D. Vanderpool Elesa W. Wedemeyer Alex Greiner University of Iowa Biochemistry Department Regulation of Mutant Actin by Actin-Binding Proteins Francis Lin Mentor: Heather Bartlett Department of Biochemistry, University of Iowa Carver College of Medicine, 51 Newton Rd., Iowa City, Iowa, 52242-1109 Doubling Time Cell Type Hours WT 2.63 115* 2.68 N115T ΔBnr 2.15 N115T ΔBnrΔBud6 2.22 116* 2.65 R116Q ΔBnr 2.10 R116Q ΔBnrΔBud6 2.11 0 5 10 15 20 25 30 0 20 40 60 80 O.D.600 Hours Cell Growth Curve WT 115* 115 ΔBnr 115 ΔBnr ΔBud6 116* 116 ΔBnr 116 ΔBnr ΔBud6 24°C 37°C 0.5M NaCl 0.9M NaClYPG *Extrapolated from previous data*Extrapolated from previous data Legend 1- WT 2- N115T ΔBnr 3- N115T ΔBnrΔBud6 4- R115Q ΔBnr 5- R115Q ΔBnrΔBud6 30°C 1000x 1x 10x 100x 1000x 1x 10x 100x 1000x 1x 10x 100x 1000x 1x 10x 100x 1 2 3 4 53 4 51 2 3 4 51 2 3 4 51 2 3 4 51 2 3 4 51 2 3 1 2 3 4 C N N115T R116Q Figure 1. Actin Monomer Figure 2. Actin Filament Bni1p or Bnr1p Actin Filament Actin Monomer Pointed End Barbed EndBni1p and Bnr1p are yeast formins. They facilitate the addition of monomers to the barbed end of the filament during polymerization. Bud6p enhances Bni1p. SUMMARY OF KEY FINDINGS • Saccharomyces cerevisiae, or budding yeast, was used as a model since it is easy to manipulate. Yeast actin shares a 94% similarity with human actin. • A spectrometer was used to determine total cell density in order to obtain a growth curve for cells expressing the mutant actins. • Spotting of cells was done using 1x, 10x, 100x, and 1000x dilutions. Stress conditions included 24°C, 30°C, and 37°C. A restricted carbon source (YPG), 0.5M NaCl, and 0.9M NaCl were additional stress conditions. METHODS The results from the spotting indicates that there is misregulation among the mutations when Bnr and/or Bud6 are deleted. The mutations display increased cell density, suggesting that the cell has lost control of its cell proliferation mechanism. All other possible ACTA2 mutations BACKGROUND OBJECTIVES METHODS VARIABLES RESULTS DISCUSSION STUDY IMPLICATIONS FUTURE RESEARCH ACKNOWLEDGEMENTS